MSLN and ovarian carcinoma: Through their experiment in patient-derived xenograft studies, the authors proved that the binding of CA125 with mesothelin promotes the metastasis of ovarian cancer, and they hypothesised a cascade of molecular events involving many different molecules (Figure 2).